NSABP Members' Area
  Password Protected - Access
  Limited to NSABP Participating
  Institutions Only


NSABP Foundation, Inc.



General NSABP Information
  Financial Conflicts of
     Interest Policy
  Coalition Comment:
     Reconfiguration
  IOM Report Group Comment
  Contact the NSABP
  Pathology Section
  Future Meetings
  NSABP Newsletters
  Media Info on STAR
  Employment

Clinical Trials Information
  Clinical Trials Overview
  Protocol Chart
  Never Say Lost

Treatment Trials Information
  Protocol B-43
  Protocol B-47
  Protocol B-51

Prevention Trials Information
  Protocol P-1 - BCPT
  Protocol P-2 - STAR
  Protocol P-5
  BreastCancerPrevention.com

Scientific Publications

Related Web Sites



Medical Search Engines



To report problems, ask
questions or make comments,
please send e-mail to:
Webmaster@nsabp.pitt.edu

NSABP Clinical Trials Overview


Protocol B-19
A Clinical Trial to Compare Sequential Methotrexate, 5-Fluorouracil (M→F) with Conventional CMF in Primary Breast Cancer Patients with Negative Nodes and Estrogen-Receptor-Negative Tumors

Specific Aims
The objective of this study is to determine whether six cycles of conventional cyclophosphamide, methotrexate and 5-fluorouracil (CMF) are as effective with respect to disease-free survival and survival as six cycles of sequential methotrexate and 5-fluorouracil (M→F) followed by leucovorin for negative-node patients whose tumors are estrogen-receptor-negative.